Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bendamustine + obinutuzumab in relapsed chronic lymphocytic leukemia followed by maintenance
2013-001088-22Phase 2Completed
- Sponsor
- München Klinik
- Start
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by München Klinik. Primary endpoint: Best overall response rate. Started Apr 2014; status: completed.
02
Drugs
bendamustineobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-001088-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001088-22.